Ozempic Offers Heart Protection Beyond Weight Loss, Groundbreaking Study Reveals Surprising Cardiovascular Benefits

Ozempic Offers Heart Protection Beyond Weight Loss, Groundbreaking Study Reveals Surprising Cardiovascular Benefits

Recent research has revealed that the heart health benefits of the weight loss drug Ozempic, which contains the active ingredient semaglutide, are not solely due to weight loss. A large study published in The Lancet and led by researchers at University College London analyzed data from more than seventeen thousand adults aged forty five and older who were overweight and had cardiovascular disease. The participants were randomly assigned to receive weekly injections of semaglutide or a placebo. The study found that semaglutide significantly reduced the risk of major cardiac events such as heart attacks, strokes, and cardiovascular deaths, regardless of how much weight each participant lost during the first four and a half months of treatment. This means that even people who lost little or no weight experienced similar heart protection as those who lost a substantial amount.

The study also looked at the impact of waist circumference, which is a marker for visceral fat, and found that a reduction in waist size was linked to about one third of the heart benefits seen in patients taking semaglutide. However, the majority of the cardiovascular benefit was not explained by changes in weight or waist size alone. This suggests that semaglutide may have direct effects on the underlying causes of heart disease, beyond just helping people lose weight. Experts say this could mean the drug might be beneficial for patients who are not severely overweight, including those with BMIs in the normal range, although further research is needed to confirm this.

Oprah Winfrey has recently spoken about her own experience with Ozempic, describing it as a tool she uses to manage her weight. She has emphasized that medication is not the only way to lose weight and that it should be seen as one option among many. Oprah has also discussed the broader cultural conversation around weight loss drugs, highlighting the need to address weight stigma and body shaming. Her openness has sparked a national dialogue about the role of prescription medications in weight management and the importance of focusing on overall health rather than just appearance.

The findings from the latest research are prompting doctors and researchers to reconsider how they approach the treatment of obesity and heart disease. While Ozempic and similar drugs were originally developed for diabetes, their ability to protect the heart even without significant weight loss is a major development. This could lead to new treatment strategies for people at high risk of cardiovascular events, regardless of their body size. As the medical community continues to explore the full range of benefits and risks associated with these medications, the conversation around weight loss and heart health is becoming more nuanced and inclusive.

Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

Jaksot(72)

GLP-1 Drug Switching Common in First Year, Study Shows Better Long-Term Weight Loss Success

GLP-1 Drug Switching Common in First Year, Study Shows Better Long-Term Weight Loss Success

A new study from UT Southwestern Medical Center, reported by HealthDay News on March 12, reveals that people often switch between GLP-1 weight-loss drugs like Ozempic and Zepbound within the first yea...

14 Maalis 2min

Ozempic and Weight Loss Drugs Reshape Health Expectations as Oprah Becomes Center of Celebrity Debate

Ozempic and Weight Loss Drugs Reshape Health Expectations as Oprah Becomes Center of Celebrity Debate

Ozempic and similar weight loss drugs have dominated health headlines again this week, and much of the conversation is circling around how these medications are reshaping expectations about body size,...

7 Maalis 4min

GLP One Drugs Transform Weight Loss and Diabetes Treatment as Market Expands to 25 Million Users by 2030

GLP One Drugs Transform Weight Loss and Diabetes Treatment as Market Expands to 25 Million Users by 2030

The landscape of weight loss medications is evolving rapidly. Just this week, Health Canada approved an expanded indication for Ozempic, semaglutide injection, to reduce the risk of major adverse card...

4 Maalis 2min

Novo Nordisk Slashes Wegovy and Ozempic Prices Up to 50 Percent Starting January 2027

Novo Nordisk Slashes Wegovy and Ozempic Prices Up to 50 Percent Starting January 2027

The weight loss drug market is undergoing a dramatic transformation this week as Novo Nordisk announced major price cuts for its popular medications Ozempic and Wegovy. Starting January 2027, the Dani...

28 Helmi 2min

Novo Nordisk Cuts Ozempic and Wegovy Prices Up to Fifty Percent Starting January 2027

Novo Nordisk Cuts Ozempic and Wegovy Prices Up to Fifty Percent Starting January 2027

Novo Nordisk announced on Tuesday that it plans to cut the list prices of its blockbuster weight-loss and diabetes drugs Ozempic and Wegovy by up to fifty percent starting January first, twenty twenty...

25 Helmi 2min

Ozempic MDL Reaches 3000 Cases Over Side Effects While Users Weigh Benefits Against Risks

Ozempic MDL Reaches 3000 Cases Over Side Effects While Users Weigh Benefits Against Risks

Recent developments in the Ozempic multidistrict litigation highlight growing concerns over side effects from the popular weight loss drug. Lawsuit Information Center reports that as of early February...

21 Helmi 2min

GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects

GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects

Recent Cochrane reviews commissioned by the World Health Organization show that blockbuster weight loss drugs like Ozempic deliver substantial results. According to ScienceDaily reporting on February ...

18 Helmi 2min

GLP-1 Weight Loss Drugs Show Promise: Semaglutide and Tirzepatide Lead Clinical Reviews in 2026

GLP-1 Weight Loss Drugs Show Promise: Semaglutide and Tirzepatide Lead Clinical Reviews in 2026

Recent news highlights ongoing developments in weight loss treatments like Ozempic, with fresh insights from clinical reviews and patient experiences. On February 11, 2026, Cochrane reviews commission...

14 Helmi 3min

Suosittua kategoriassa Politiikka ja uutiset

uutiscast
aikalisa
politiikan-puskaradio
ootsa-kuullut-tasta-2
rss-ootsa-kuullut-tasta
rss-pinnalla
tervo-halme
rss-vaalirankkurit-podcast
rss-podme-livebox
aihe
rss-asiastudio
the-ulkopolitist
rss-tasta-on-kyse-ivan-puopolo-verkkouutiset
rss-girls-finish-f1rst
otetaan-yhdet
et-sa-noin-voi-sanoo-esittaa
rss-50100-podcast
rss-polikulaari-pitka-kiekko-ja-muut-ts-podcastit
rss-ulkopoditiikkaa
rss-kaikki-uusiksi